Genmab AS
GMAB: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 5,977.00 | Smmhmdg | Knwzsdjdn |
Narrow-Moat Genmab Reports in Line Q1 Results; Maintaining DKK 2220 FVE, Shares Fairly Valued
Genmab reported solid first-quarter results in line with our expectations. Revenue of DKK 2.1 billion increased 34% from the prior-year period, which was primarily due to continued strong demand for Darzalex, contributing to a 36% year-over-year increase in Darzalex net sales. We maintain our fair value estimate of DKK 2,220 per share and view shares as fairly valued, currently trading in 3-star territory.